Marcus Devlin, OD
Optometrist · Philadelphia, PANPI 1336338540
Payments from drug & device makers
Across 89 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$480
- Johnson & Johnson Vision Care, Inc.$411
- Coopervision Inc.$255
- Sun Pharmaceutical Industries Inc.$218
- Tarsus Pharmaceuticals, Inc.$139
- Bausch & Lomb Americas Inc.$135
- plus $397 from 6 others
What the payments were for
- Consulting fees$1005%
- Speaking & faculty fees$502%
- Food & beverage$1,88493%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 14 | $480 |
| Johnson & Johnson Vision Care, Inc. | 18 | $411 |
| Coopervision Inc. | 14 | $255 |
| Sun Pharmaceutical Industries Inc. | 10 | $218 |
| Tarsus Pharmaceuticals, Inc. | 4 | $139 |
| Bausch & Lomb Americas Inc. | 7 | $135 |
| Novartis | 2 | $122 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $85 |
| Visioneering Technologies, Inc. | 10 | $82 |
| Oyster Point Pharma, Inc. | 2 | $46 |
| Shire North American Group Inc | 2 | $38 |
| AbbVie | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Precision 1$106
- XIIDRA$102
How this compares
$2,034 in reported general payments places this provider in the 75th percentile of 2,165 optometrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate | 14 | $2,887 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 21 | $628 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 18 | $515 |
| Latanoprost | 56 | $505 |
| Prednisolone Acetate | 16 | $500 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 49 | $445 |
| Azithromycin | 13 | $28 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Philadelphia
- Shivakhaami MeiyeppenPhiladelphia$100K
- Gretchen BrewerPhiladelphia$79K
- Alan KabatPhiladelphia$49K
- Melissa TregoPhiladelphia$46K
- Elizabeth TonkeryPhiladelphia$40K
- Clark ChangPhiladelphia$37K
- Tu DinhPhiladelphia$28K
- Justin ShermanPhiladelphia$17K
- Diana ChuongPhiladelphia$10K
- David DuffyPhiladelphia$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.